Dissemin is shutting down on January 1st, 2025

Published in

Lippincott, Williams & Wilkins, NeuroReport, 7(14), p. 1051-1054, 2003

DOI: 10.1097/01.wnr.0000073685.00308.89

Lippincott, Williams & Wilkins, NeuroReport, 7(14), p. 1051-1054, 2003

DOI: 10.1097/00001756-200305230-00029

Links

Tools

Export citation

Search in Google Scholar

Assessing disease onset and progression in the SOD1 mouse model of ALS:

Journal article published in 2003 by Patrick Weydt, Michel Kliot, Thomas M??ller, So Yon Hong ORCID, Thomas Möller
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

SOD1 transgenic mice are the most widely used animal model of amyotrophic lateral sclerosis (ALS). In addition to providing valuable insights into the pathogenesis of ALS, these animals are used intensively in many laboratories as an in vivo model for investigating novel therapeutic interventions towards this devastating motorneuron disease. Such pre-clinical studies require objective and reliable quantification of the clinical phenotype of individual mice, most importantly of the neuromuscular abnormalities. Here we compare four parameters of the clinical phenotype: motor signs, body weight, rotarod performance and paw grip endurance for their usefulness in monitoring the SOD1 mouse model. We found that paw grip endurance is a sensitive and inexpensive alternative to the widely used rotarod test.